Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 515 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Target Lesion Clear all
Completed Early Phase 1 Interventional

Dexamethasone to Target Stress and Immune System Mechanisms Underlying Alcohol Craving

NCT05305404
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Dexamethasone Oral, Placebo
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 25, 2026, 5:43 PM EDT
Completed Not applicable Interventional

Framing Eighteen Coils in Cerebral Aneurysms Trial

NCT01655784
View directory record Official record
Conditions
Cerebral Aneurysm
Interventions
Coil Embolization with larger Diameter Coils, Coil Embolization with Standard Diameter Coils
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
24
States / cities
Fresno, California • Englewood, Colorado • Gainesville, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 25, 2026, 5:43 PM EDT
Completed Phase 1Phase 2 Interventional

Deep Brain Therapy With Low-intensity Ultrasound for Generalized Chronic Pain

NCT05674903
View directory record Official record
Conditions
Chronic Pain, Chronic Pain Syndrome, Widespread Chronic Pain
Interventions
Verum stimulation with Diadem prototype, Sham stimulation with Diadem prototype
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 25, 2026, 5:43 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Sleep Technology Intervention to Target Cardiometabolic Health

NCT04766424
View directory record Official record
Conditions
Elevated Blood Pressure, Habitual Sleep Duration of Less Than or Equal to 7 Hours
Interventions
Sleep extension intervention, Health education
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 25, 2026, 5:43 PM EDT
Recruiting Phase 1 Interventional

Safety and Target Engagement of Centella Asiatica in Cognitive Impairment

NCT05591027
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Centella asiatica product, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
60 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Oct 25, 2026, 5:43 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC

NCT02658097
View directory record Official record
Conditions
Stage IV Non-Small Cell Lung Cancer
Interventions
Pembrolizumab, Single Fraction Radiation Therapy
Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 25, 2026, 5:43 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of ASCT-83 in Healthy Adults

NCT07363395
View directory record Official record
Conditions
Neuropathic Pain
Interventions
ASCT-83, Placebo
Drug
Lead sponsor
Alcamena Stem Cell Therapeutics
Industry
Eligibility
18 Years to 64 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 25, 2026, 5:43 PM EDT
Recruiting Phase 2 Interventional

Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer

NCT06437574
View directory record Official record
Conditions
Prostate Cancer
Interventions
Vytorin, Ezetimibe
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 25, 2026, 5:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Repeated Virtual Reality Training on Markers of Stress

NCT07770880
View directory record Official record
Conditions
Stress, Acute Stress Reaction, Virtual Reality, Active Shooter, Law Enforcement Training
Interventions
Active Shooter, Target Practice
Other
Lead sponsor
Texas State University
Other
Eligibility
18 Years to 39 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Marcos, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 25, 2026, 5:43 PM EDT
Completed Phase 1 Interventional

A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors

NCT05025085
View directory record Official record
Conditions
Advanced Cancer
Interventions
AGEN1777, a PD-1 inhibitor
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
Grand Rapids, Michigan • Southfield, Michigan • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 25, 2026, 5:43 PM EDT
Completed No phase listed Observational

Advanced MR Imaging in Sarcoma Patients

NCT02705391
View directory record Official record
Conditions
Sarcoma
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
7 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 25, 2026, 5:43 PM EDT
Completed Not applicable Interventional Results available

Accelerated TMS to a Novel Brain Target in MDD and PTSD

NCT03114891
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Major Depressive Disorder
Interventions
Transcranial Magnetic Stimulation (TMS), Task, fMRI-guided TMS target
Device · Behavioral · Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 25, 2026, 5:43 PM EDT
Completed Phase 1 Interventional

Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA)

NCT02095548
View directory record Official record
Conditions
Moderate to Severe Osteoarthritis
Interventions
SM04690, 0.03mg/2mL, SM04690, 0.07mg/2mL, SM04690, 0.23mg/2mL, Placebo
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
50 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Tucson, Arizona • El Cajon, California • Walnut Creek, California + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Oct 25, 2026, 5:43 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety Study of ORG 34517 for Major Depression With Psychotic Features

NCT00226278
View directory record Official record
Conditions
Major Depressive Disorder, Psychotic Disorders
Interventions
ORG 34517
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2008 · Synced Oct 25, 2026, 5:43 PM EDT
Completed Not applicable Interventional Results available

Physical Activity Choices Everyday

NCT03824769
View directory record Official record
Conditions
Obesity
Interventions
Weight Loss Maintenance + Healthy Thinking, Weight Loss Maintenance Treatment + Future Thinking
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 70 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 25, 2026, 5:43 PM EDT
Terminated Early Phase 1 Interventional Results available

A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer

NCT03519308
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Nivolumab, Nab-Paclitaxel, Gemcitabine, Paricalcitol
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 25, 2026, 5:43 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Multimodal Assessment of Cannabinoid Target Engagement in Adults With Obsessive-Compulsive Disorder

NCT04880278
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Nabilone, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Oct 25, 2026, 5:43 PM EDT
Recruiting Phase 1 Interventional

Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

NCT07090148
View directory record Official record
Conditions
Prostate Cancer Patients, Non-castrate Prostate Cancer, Recurrent Prostate Cancer, Oligometastatic Prostate Cancer (OMPC)
Interventions
pTVG-HP DNA vaccine, Anti-PD-1 monoclonal antibody
Biological · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 25, 2026, 5:43 PM EDT
Completed No phase listed Observational

HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network

NCT01474811
View directory record Official record
Conditions
Hepatitis C
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
13,559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
55
States / cities
Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 25, 2026, 5:43 PM EDT
Completed No phase listed Observational

Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia

NCT01076569
View directory record Official record
Conditions
Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Leukemia, Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Minimally Differentiated Myeloid Leukemia (M0), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Recurrent Childhood Acute Myeloid Leukemia, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Monrovia, California
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 25, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes

NCT01336023
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide, insulin degludec, liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
146
States / cities
Birmingham, Alabama • Anaheim, California • Bermuda Dunes, California + 126 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 25, 2026, 5:43 PM EDT
Completed No phase listed Observational

Improving Anticoagulant Therapy Through Warfarin Metabolite Profiling

NCT01964794
View directory record Official record
Conditions
Stable Target INR
Interventions
Not listed
Lead sponsor
University of Arkansas
Other
Eligibility
60 Years to 69 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 25, 2026, 5:43 PM EDT
Terminated Not applicable Interventional Results available

LUPUS Brain: tACS to Target the Neurophysiology of Depression, Cognitive Deficits, and Pain in Patients With SLE

NCT04141046
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Depression
Interventions
XCSITE100 Stimulator - Individualized theta-tACS, XCSITE100 Stimulator - Individualized alpha-tACS, XCSITE100 Stimulator - Active Sham
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 25, 2026, 5:43 PM EDT
Recruiting Phase 2 Interventional

ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer

NCT04523857
View directory record Official record
Conditions
Breast Cancer
Interventions
Abemaciclib, Hydroxychloroquine
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 25, 2026, 5:43 PM EDT